CN117255791A - 化合物、内皮素a受体拮抗剂及医药组合物 - Google Patents

化合物、内皮素a受体拮抗剂及医药组合物 Download PDF

Info

Publication number
CN117255791A
CN117255791A CN202280032424.9A CN202280032424A CN117255791A CN 117255791 A CN117255791 A CN 117255791A CN 202280032424 A CN202280032424 A CN 202280032424A CN 117255791 A CN117255791 A CN 117255791A
Authority
CN
China
Prior art keywords
mmol
added
reaction mixture
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280032424.9A
Other languages
English (en)
Chinese (zh)
Inventor
田中圭悟
二宫智尚
远又庆英
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yake Pharmaceutical Co ltd
Original Assignee
Yake Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yake Pharmaceutical Co ltd filed Critical Yake Pharmaceutical Co ltd
Publication of CN117255791A publication Critical patent/CN117255791A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202280032424.9A 2021-06-22 2022-06-21 化合物、内皮素a受体拮抗剂及医药组合物 Pending CN117255791A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021103047 2021-06-22
JP2021-103047 2021-06-22
PCT/JP2022/024638 WO2022270487A1 (ja) 2021-06-22 2022-06-21 化合物、エンドセリンａ受容体拮抗剤及び医薬組成物

Publications (1)

Publication Number Publication Date
CN117255791A true CN117255791A (zh) 2023-12-19

Family

ID=84545734

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280032424.9A Pending CN117255791A (zh) 2021-06-22 2022-06-21 化合物、内皮素a受体拮抗剂及医药组合物

Country Status (12)

Country Link
US (1) US20240287053A1 (https=)
EP (1) EP4361146A4 (https=)
JP (1) JP7531947B2 (https=)
KR (1) KR20240022646A (https=)
CN (1) CN117255791A (https=)
AR (1) AR126178A1 (https=)
AU (1) AU2022297082B2 (https=)
BR (1) BR112023019460A2 (https=)
CA (1) CA3217189A1 (https=)
IL (1) IL306095A (https=)
MX (1) MX2023014455A (https=)
WO (1) WO2022270487A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025183466A (ja) * 2022-11-11 2025-12-17 株式会社アークメディスン 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027979A1 (en) * 1993-05-20 1994-12-08 Immunopharmaceutics, Inc. Sulfonamides and derivatives thereof that modulate the activity of endothelin
CN104039781A (zh) * 2012-01-31 2014-09-10 卫材R&D管理有限公司 西他生坦衍生物
CN104169257A (zh) * 2012-02-27 2014-11-26 勃林格殷格翰国际有限公司 用作smac模拟物的新的6-炔基吡啶

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514696A (en) 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
ATE243203T1 (de) 1995-04-04 2003-07-15 Texas Biotechnology Corp Thienyl-, furyl-, pyrrolyl- und biphenylsulfonamide und derivate zur modulation der endothelin-aktivität
UA58494C2 (uk) 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
WO1998033781A1 (en) 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
JP3455233B2 (ja) 1997-04-28 2003-10-14 テキサス・バイオテクノロジー・コーポレイシヨン エンドテリン介在障害治療用のスルホンアミド類
MXPA02006461A (es) * 1999-12-31 2003-09-05 Texas Biotechnology Corp Sulfonamidas y derivados de las mismas que modulan la actividad de endotelina.
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027979A1 (en) * 1993-05-20 1994-12-08 Immunopharmaceutics, Inc. Sulfonamides and derivatives thereof that modulate the activity of endothelin
CN104039781A (zh) * 2012-01-31 2014-09-10 卫材R&D管理有限公司 西他生坦衍生物
CN104169257A (zh) * 2012-02-27 2014-11-26 勃林格殷格翰国际有限公司 用作smac模拟物的新的6-炔基吡啶

Also Published As

Publication number Publication date
IL306095A (en) 2023-11-01
JP7531947B2 (ja) 2024-08-13
US20240287053A1 (en) 2024-08-29
CA3217189A1 (en) 2022-12-29
TW202317555A (zh) 2023-05-01
BR112023019460A2 (pt) 2024-01-23
JPWO2022270487A1 (https=) 2022-12-29
AU2022297082A1 (en) 2023-09-28
WO2022270487A1 (ja) 2022-12-29
KR20240022646A (ko) 2024-02-20
AR126178A1 (es) 2023-09-27
EP4361146A4 (en) 2025-06-18
EP4361146A1 (en) 2024-05-01
AU2022297082B2 (en) 2024-04-18
MX2023014455A (es) 2023-12-15

Similar Documents

Publication Publication Date Title
JP6670906B2 (ja) 新しい３，４−ジヒドロ−２ｈ−イソキノリン−１−オン及び２，３−ジヒドロ−イソインドール−１−オン化合物
JPWO2012102254A1 (ja) インドール誘導体、またはその薬理学的に許容される塩
US10106523B2 (en) Amide compound
WO2011013623A1 (ja) インドール誘導体、またはその薬理学的に許容される塩
JP2019014738A (ja) 新規３，４−ジヒドロ−２ｈ−イソキノリン−１−オン及び２，３−ジヒドロ−イソインドール−１−オン化合物
CN117255791A (zh) 化合物、内皮素a受体拮抗剂及医药组合物
RU2681316C2 (ru) Производные циклогексилпиридина
RU2831561C2 (ru) Соединение, антагонист эндотелинового рецептора a и фармацевтическая композиция
TWI918959B (zh) 化合物、內皮素a受體拮抗劑及醫藥組合物
HK40108888A (en) Compound, endothelin-a receptor antagonist, and pharmaceutical composition
JP2012167085A (ja) インドール誘導体、またはその薬理学的に許容される塩の医薬用途
CN101262864A (zh) 饱和o-杂环取代的烷酰胺
CN102171191A (zh) 吲唑衍生物
WO1998057938A1 (en) Substituted lower alkanesulfonamide derivatives and pharmaceutical composition containing the same
JPWO2016143200A1 (ja) 二環式ピリジン化合物
WO2014190942A1 (zh) 一类吲哚类化合物、其制备方法、药物组合物及应用
CN105143205B (zh) 新的3,4‑二氢‑2h‑异喹啉‑1‑酮和2,3‑二氢‑异吲哚‑1‑酮化合物
WO2000005209A1 (fr) GUAIACOXYPROPANOLAMINES A ACTIVITE α/β-ADRENOLYTIQUE
JP2007056005A (ja) 新規なベンゾフラン誘導体、それを含有する医薬組成物およびそれらの用途
EA009464B1 (ru) Бензамиды 4-(аминометил)пиперидина, замещённого гидроксикарбонилфенилом, в качестве антагонистов 5нт-рецепторов
HK1213564B (en) 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds
JP2003089657A (ja) 眼科用医薬組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination